To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Antibodies by Design and JPT Peptide Technologies Announce Cooperation Agreement
Read time: Less than a minute
Antibodies by Design and JPT Peptide Technologies have announced the start of a co-marketing agreement between the two companies.
Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT.
Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan.
"We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers," stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG.
He adds, "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe."
"MorphoSys' unique antibody repertoire is the ideal complement to our immunology tools program which includes the peptide array platforms PepSpot™ and PepStar™ plus the novel PepMix™ technology for effective T-lymphocyte stimulation," said Holger Wenschuh, Managing Director of JPT.
He adds, "This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services."
Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT.
Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan.
"We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers," stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG.
He adds, "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe."
"MorphoSys' unique antibody repertoire is the ideal complement to our immunology tools program which includes the peptide array platforms PepSpot™ and PepStar™ plus the novel PepMix™ technology for effective T-lymphocyte stimulation," said Holger Wenschuh, Managing Director of JPT.
He adds, "This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services."
